Delhi High Court Denies Injunction in BEVETEX vs BEVATAS Pharmaceutical Trademark Dispute

In Sun Pharma Laboratories Ltd. vs. Intas Pharmaceuticals Ltd.¹, the Delhi High Court examined whether the pharmaceutical trademarks “BEVETEX” and “BEVATAS” were deceptively similar. The Court ultimately refused to grant relief, holding that no likelihood of confusion existed between the two marks.

Summary

In a significant ruling concerning trademark infringement in the pharmaceutical sector, the Delhi High Court refused to grant relief to the plaintiff, holding that no likelihood of confusion existed between the competing marks “BEVETEX” and “BEVATAS.”

The Court emphasized that in cases involving specialized drugs administered under expert supervision, the threshold for establishing confusion is higher and must be assessed in light of the nature of the products and their usage.

Facts of the Case

The plaintiff, Sun Pharma Laboratories Ltd., instituted a suit seeking permanent injunction against the defendant for alleged infringement of its registered trademark “BEVETEX,” along with claims of passing off, unfair competition, and dilution. The plaintiff’s drug, containing the molecule Paclitaxel, is used for treating breast cancer and other conditions.

The defendant, Intas Pharmaceuticals Ltd., marketed a drug under the mark “BEVATAS,” containing the molecule Bevacizumab, used for treating different types of cancers.

The plaintiff contended that the marks were deceptively similar and that confusion between the two could lead to serious, even life-threatening consequences due to incorrect administration.

The trial court had earlier refused interim relief, and subsequent appellate proceedings, including before the Supreme Court, did not grant any interim protection, leading to final adjudication by the High Court.

Issues before the Court

1. Whether the defendant’s use of the mark “BEVATAS” amounts to infringement and passing off of the plaintiff’s registered trademark “BEVETEX”.
2. Whether there exists a likelihood of confusion or deception, particularly in the context of pharmaceutical products.

Findings of the Court

Comparison of the Competing Marks

The Court undertook a comprehensive analysis of the competing marks, the nature of the drugs, and the surrounding circumstances of their use. It observed that although both marks are used in relation to pharmaceutical products, they are structurally, phonetically, and compositionally distinct when considered as a whole.

The Court emphasized that trademark comparison must adhere to the anti-dissection rule and be based on overall impression rather than isolated similarities.

Distinct Drug Compositions and Administration

Importantly, the Court noted that the competing drugs contain entirely different active ingredients — Paclitaxel and Bevacizumab — belonging to different pharmacological classes, with distinct mechanisms, indications, and toxicity profiles.

The drugs are not interchangeable and are prescribed and administered strictly under the supervision of specialized oncologists in controlled medical settings.

Application of the Cadila Standard

The Court distinguished the applicability of the principle laid down in Cadila Healthcare Ltd. vs. Cadila Pharmaceuticals Ltd.², noting that while a stricter standard applies in pharmaceutical cases, the factual matrix here significantly reduces the likelihood of confusion. Key factors included:

• The nature of administration under expert supervision
• Distinct drug compositions and pharmacological classes
• Controlled medical settings for prescription and dispensation

Absence of Actual Confusion and Goodwill

The Court further held that the plaintiff had failed to demonstrate actual confusion or establish sufficient goodwill in the mark, especially given the delayed commercial use of the mark despite its earlier registration.

The Court also took into account additional mitigating factors:

• Price differences between the two drugs
• Different modes of administration
• The specialized nature of the drugs and their consumer base

Held

The Delhi High Court dismissed the suit and declined to grant any injunctive relief, holding that no case of infringement or passing off was made out.

It concluded that the competing marks did not create a likelihood of confusion in the relevant market and that the plaintiff failed to establish entitlement to protection.

Conclusion

This judgment provides an important clarification in pharmaceutical trademark jurisprudence by balancing the strict standard of confusion with practical realities of drug administration. While reaffirming that heightened caution is necessary in cases involving medicinal products, the Court underscored that such caution cannot override a contextual analysis of the market, product characteristics, and consumer base.

The ruling signals that in highly specialized medical contexts, factors such as expert supervision, distinct compositions, and controlled distribution channels may significantly diminish the risk of confusion, thereby limiting the scope of trademark enforcement.